Koen van Besien

InstitutionDepartment of Medicine
AddressNew York
New York
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 2 Covid-19 publications, with a maximum of 2 publications in July 2020
    All Publications
    Bar chart showing 174 publications over 19 distinct years, with a maximum of 16 publications in 2009
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shah MA, Emlen MF, Shore T, Mayer S, Leonard JP, Rossi A, Martin P, Ritchie E, Niesvizky R, Pastore R, Cigler T, De Sancho M, Scheff R, Van Besien K, Roboz G, Nanus D, Goldstein P, Scrimenti L, Hidalgo M. Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA Cancer J Clin. 2020 09; 70(5):349-354. PMID: 32662880.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    2. Mina A, van Besien K, Platanias LC. Hematological manifestations of COVID-19. Leuk Lymphoma. 2020 12; 61(12):2790-2798. PMID: 32643489.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    3. Sailer V, Eng KW, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E, Cyrta J, Rao R, Sahota S, Pauli C, Beg S, Motanagh S, Kossai M, Fontunge J, Puca L, Rennert H, Zhaoying Xiang J, Greco N, Kim R, MacDonald TY, McNary T, Blattner-Johnson M, Schiffman MH, Faltas BM, Greenfield JP, Rickman D, Andreopoulou E, Holcomb K, Vahdat LT, Scherr DS, van Besien K, Barbieri CE, Robinson BD, Fine HA, Ocean AJ, Molina A, Shah MA, Nanus DM, Pan Q, Demichelis F, Tagawa ST, Song W, Mosquera JM, Sboner A, Rubin MA, Elemento O, Beltran H. Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precis Oncol. 2019; 3. PMID: 31592503.
      Citations: 8     
    4. Choe HK, van Besien K. Donor graft genotypes versus leukemia. Leuk Lymphoma. 2019 07; 60(7):1606-1607. PMID: 31238818.
      Citations:    Fields:    Translation:Humans
    5. Gergis U, van Besien K. Tocilizumab, in search for a role in acute GVHD. Leuk Lymphoma. 2019 09; 60(9):2101-2103. PMID: 31238760.
      Citations: 1     Fields:    Translation:HumansAnimals
    6. Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, Phillips AA, Rossi A, Coleman M, van Besien K, Shore TB. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2019 12; 54(12):2027-2038. PMID: 31190006.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    7. Allan JN, Van Besien K. It's not all about the CNS. High dose methotrexate in DLBCL. Leuk Lymphoma. 2019 08; 60(8):1845-1847. PMID: 31120336.
      Citations: 1     Fields:    Translation:Humans
    8. Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019 07; 60(7):1626-1631. PMID: 30997845.
      Citations: 8     Fields:    Translation:Humans
    9. Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leuk Lymphoma. 2019 07; 60(7):1693-1696. PMID: 30741059.
      Citations: 7     Fields:    Translation:HumansCells
    10. Glynn S, Lipkin S, Zhang T, Sboner A, Elemento O, Van Besien K, Beltran H. The application of precision medicine in diagnosing familial Mediterranean fever. Leuk Lymphoma. 2019 08; 60(8):2091-2093. PMID: 30698071.
      Citations:    Fields:    Translation:HumansCells
    11. Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H. Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Exp Hematol Oncol. 2019; 8:1. PMID: 30622841.
      Citations: 2     
    12. Satlin MJ, Chavda KD, Baker TM, Chen L, Shashkina E, Soave R, Small CB, Jacobs SE, Shore TB, van Besien K, Westblade LF, Schuetz AN, Fowler VG, Jenkins SG, Walsh TJ, Kreiswirth BN. Colonization With Levofloxacin-resistant Extended-spectrum ß-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2018 11 13; 67(11):1720-1728. PMID: 29701766.
      Citations: 11     Fields:    Translation:HumansCells
    13. Eichenberger EM, Soave R, Zappetti D, Small CB, Shore T, van Besien K, Douglass C, Westblade LF, Satlin MJ. Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2019 07; 54(7):1058-1066. PMID: 30385869.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    14. Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 09; 103(9):1577. PMID: 30171018.
      Citations:    Fields:    
    15. Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, Cushing MM, Singh AD, van Besien K. Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma. 2018 12; 59(12):2829-2835. PMID: 29790808.
      Citations:    Fields:    Translation:HumansCells
    16. Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 05; 103(5):770-777. PMID: 29419425.
      Citations: 17     Fields:    Translation:HumansCells
    17. Sfeir MM, Schuetz A, Van Besien K, Borczuk AC, Soave R, Jenkins SG, Walsh TJ, Small CB. Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes. J Clin Pathol. 2018 Jul; 71(7):626-630. PMID: 29367301.
      Citations: 5     Fields:    Translation:HumansCells
    18. Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456. PMID: 29330398.
      Citations: 24     Fields:    Translation:Humans
    19. Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004. PMID: 29288821.
      Citations: 5     Fields:    Translation:Humans
    20. Reich-Slotky R, Cushing MM, Hsu YS, Ancharski M, Rojas JM, Scrimenti LM, Robilio S, Assalone D, Roselli T, Guarneri D, Vasovic LV, Goel R, Shore T, van Besien K. Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cells-a single-institution experience. Transfusion. 2018 02; 58(2):339-344. PMID: 29193156.
      Citations:    Fields:    Translation:HumansCells
    21. Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, Shore TB, van Besien K. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365. PMID: 29128555.
      Citations: 2     Fields:    Translation:Humans
    22. Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu JM, Niesvizky R, Mark TM, Pearse R, Rossi A, van Besien K. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biol Blood Marrow Transplant. 2018 02; 24(2):288-293. PMID: 29061534.
      Citations: 2     Fields:    Translation:HumansCells
    23. Choe HK, van Besien K. Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant. Leuk Lymphoma. 2018 02; 59(2):272-273. PMID: 28812411.
      Citations: 3     Fields:    Translation:Humans
    24. Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. Leuk Lymphoma. 2018 01; 59(1):256-258. PMID: 28573908.
      Citations: 2     Fields:    Translation:HumansCells
    25. Kanaan SB, Gammill HS, Harrington WE, De Rosa SC, Stevenson PA, Forsyth AM, Allen J, Cousin E, van Besien K, Delaney CS, Nelson JL. Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant. Oncoimmunology. 2017; 6(5):e1311436. PMID: 28638735.
      Citations: 11     
    26. Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937. PMID: 28285081.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    27. Choe HK, Gergis U, Mayer SA, Nagar H, Phillips AA, Shore TB, Smith MJ, van Besien K. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Transplantation. 2017 Jan; 101(1):e34-e38. PMID: 27764032.
      Citations: 1     Fields:    Translation:Humans
    28. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. PMID: 28018601.
      Citations: 9     Fields:    
    29. Mayer S, van Besien K. Second allogeneic transplantation: ever? never? or sometimes. Leuk Lymphoma. 2017 06; 58(6):1279-1280. PMID: 27842447.
      Citations:    Fields:    Translation:Humans
    30. van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Haplo-cord transplant: HLA-matching determines graft dominance. Leuk Lymphoma. 2017 06; 58(6):1512-1514. PMID: 27786572.
      Citations: 2     Fields:    Translation:HumansCells
    31. Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, Artz A, van Besien K, Larson RA, Lee MK, Segal JP, King MC, Walsh T, Shimamura A, Keel SB, Churpek JE, Godley LA. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103. PMID: 27497531.
      Citations: 14     Fields:    Translation:Humans
    32. van Besien K, Childs R. Haploidentical cord transplantation-The best of both worlds. Semin Hematol. 2016 10; 53(4):257-266. PMID: 27788764.
      Citations: 5     Fields:    Translation:Humans
    33. Dierickx D, Sprangers B, Van Besien K. HLA: revisiting an old suspect in the complex pathogenesis of posttransplant lymphoproliferative disorders. Leuk Lymphoma. 2016 10; 57(10):2241-2. PMID: 27379564.
      Citations:    Fields:    Translation:Humans
    34. van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Cord blood chimerism and relapse after haplo-cord transplantation. Leuk Lymphoma. 2017 02; 58(2):288-297. PMID: 27333804.
      Citations: 7     Fields:    Translation:Humans
    35. Thomas CM, Ippoliti C, Roboz GJ, Feldman E, Savva D, James S, van Besien K. Clofarabine as a bridge to hematopoietic stem cell transplant. Leuk Lymphoma. 2017 01; 58(1):230-232. PMID: 27240704.
      Citations:    Fields:    Translation:Humans
    36. Isa F, Saito K, Huang YT, Schuetz A, Babady NE, Salvatore S, Pessin M, van Besien K, Perales MA, Giralt S, Sepkowitz K, Papanicolaou GA, Soave R, Kamboj M. Implementation of Molecular Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers. Clin Infect Dis. 2016 08 15; 63(4):565-8. PMID: 27199460.
      Citations: 5     Fields:    Translation:HumansAnimalsPHPublic Health
    37. Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016 08; 22(8):1348-1356. PMID: 27131865.
      Citations: 20     Fields:    Translation:Humans
    38. Cirrone F, Ippoliti C, Wang H, Zhou XK, Gergis U, Mayer S, Shore T, van Besien K. Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation. Leuk Lymphoma. 2016 11; 57(11):2555-9. PMID: 26984480.
      Citations: 5     Fields:    Translation:HumansCells
    39. Salvatore M, Satlin MJ, Jacobs SE, Jenkins SG, Schuetz AN, Moss RB, Van Besien K, Shore T, Soave R. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. Biol Blood Marrow Transplant. 2016 May; 22(5):965-70. PMID: 26904972.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    40. Tsai SB, Liu H, Shore T, Fan Y, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Martinez G, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072. PMID: 26912055.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    41. Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May; 16(5):297-303. PMID: 27025789.
      Citations: 5     Fields:    Translation:Humans
    42. van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43. PMID: 26869630.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    43. Reich-Slotky R, Bachegowda LS, Ancharski M, Gergis U, van Besien K, Cushing MM. Engraftment for CD34 selected stem cell products is not compromised by cryopreservation. Transfusion. 2016 Apr; 56(4):893-8. PMID: 26661996.
      Citations: 3     Fields:    Translation:HumansCells
    44. Patel K, Parmar S, Shah S, Shore T, Gergis U, Mayer S, van Besien K. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):456-61. PMID: 26524732.
      Citations: 3     Fields:    Translation:Humans
    45. van Besien K. Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2035-2036. PMID: 26463649.
      Citations:    Fields:    Translation:Humans
    46. Jacobs SE, Lamson DM, Soave R, Guzman BH, Shore TB, Ritchie EK, Zappetti D, Satlin MJ, Leonard JP, van Besien K, Schuetz AN, Jenkins SG, George KS, Walsh TJ. Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. J Clin Virol. 2015 Oct; 71:51-8. PMID: 26370315.
      Citations: 11     Fields:    Translation:HumansCells
    47. Storch E, Mark T, Avecilla S, Pagan C, Rhodes J, Shore T, van Besien K, Cushing M. A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. Transfusion. 2015 Aug; 55(8):2010-6. PMID: 25808119.
      Citations: 2     Fields:    Translation:HumansCells
    48. Lindemans CA, van Besien K. Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cells. Cytotherapy. 2015 Jun; 17(6):723-729. PMID: 25791069.
      Citations: 5     Fields:    Translation:Humans
    49. Phillips AA, van Besien K. A new "age" for high dose therapy and autologous stem cell transplant. Leuk Lymphoma. 2015; 56(8):2233-4. PMID: 25641430.
      Citations:    Fields:    Translation:Humans
    50. Liu H, van Besien K. Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors? Curr Hematol Malig Rep. 2015 Mar; 10(1):1-7. PMID: 25667129.
      Citations: 5     Fields:    Translation:Humans
    51. Segovia J, van Besien K. Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned. Leuk Lymphoma. 2015 Apr; 56(4):841-2. PMID: 25495172.
      Citations: 1     Fields:    Translation:Humans
    52. Reich-Slotky R, Bachegowda LS, Ancharski M, Mendeleyeva L, Rubinstein P, Rennert H, Shore T, van Besien K, Cushing M. How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions. Transfusion. 2015 Jun; 55(6):1147-53. PMID: 25652820.
      Citations: 2     Fields:    Translation:HumansCells
    53. Preeshagul IR, Van Besien K, Mark TM. Controversies in multiple myeloma: to transplant or not? Curr Hematol Malig Rep. 2014 Dec; 9(4):360-7. PMID: 25145553.
      Citations: 1     Fields:    Translation:Humans
    54. Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol. 2014 Sep; 12(9):565-73. PMID: 25654478.
      Citations: 15     Fields:    Translation:Humans
    55. van Besien K. Advances in umbilical cord blood transplant: an overview of the 12th International Cord Blood Symposium, San Francisco, 5-7 June 2014. Leuk Lymphoma. 2015 Apr; 56(4):877-81. PMID: 25058374.
      Citations:    Fields:    Translation:Humans
    56. Polliack A, Seymour J, Van Besien K, Treadway A. Statement of Retraction: Huang H, Wu D, Fu J, Chen G. "multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid". Leuk Lymphoma. 2014 Jun; 55(6):1437. PMID: 24850142.
      Citations:    Fields:    
    57. van Besien K, Furman RR. To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant? Leuk Lymphoma. 2014 Jun; 55(6):1221-2. PMID: 24745938.
      Citations:    Fields:    Translation:HumansCells
    58. Petri CR, O'Donnell PH, Cao H, Artz AS, Stock W, Wickrema A, Hard M, van Besien K. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73. PMID: 24564572.
      Citations: 6     Fields:    Translation:Humans
    59. Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9. PMID: 24816237.
      Citations: 65     Fields:    Translation:Humans
    60. van Besien K. Advances in umbilical cord blood transplant: a summary of the 11th International Cord Blood Symposium, San Francisco, 6-8 June 2013. Leuk Lymphoma. 2014 Aug; 55(8):1735-8. PMID: 24180330.
      Citations: 2     Fields:    Translation:Humans
    61. Satlin MJ, Soave R, Racanelli AC, Shore TB, van Besien K, Jenkins SG, Walsh TJ. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014 Dec; 55(12):2858-65. PMID: 24559288.
      Citations: 12     Fields:    Translation:HumansCells
    62. Kosuri S, van Besien K. Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma. Leuk Lymphoma. 2014 Mar; 55(3):476-7. PMID: 24471910.
      Citations:    Fields:    Translation:Humans
    63. Eikmans M, van Halteren AG, van Besien K, van Rood JJ, Drabbels JJ, Claas FH. Naturally acquired microchimerism: implications for transplantation outcome and novel methodologies for detection. Chimerism. 2014; 5(2):24-39. PMID: 24762743.
      Citations: 11     Fields:    Translation:HumansAnimals
    64. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70. PMID: 24065243.
      Citations: 53     Fields:    Translation:Humans
    65. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013 Sep 01; 31(25):3100-9. PMID: 23897963.
      Citations: 53     Fields:    Translation:Humans
    66. Polliack A, Van Besien K, Seymour J, Treadway A. Statement of retraction. Avilés A, Fernándezb R, Pérez F, Nambo MJ, Neri N, Talavera A, Castañeda C,González M, Cleto. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma. 2013 Jul; 54(7):1571. PMID: 23777388.
      Citations:    Fields:    
    67. Gergis U, Roboz G, Shore T, Ritchie E, Mayer S, Wissa U, McKenna M, Christos P, Pearse R, Mark T, Scandura J, van Besien K, Feldman E. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1040-5. PMID: 23648237.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    68. Lin RJ, Larson RA, van Besien K, Rich ES. Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation. Case Rep Hematol. 2013; 2013:140138. PMID: 23607004.
      Citations:    
    69. van Besien K, Liu HT, Artz A. Microchimerism and allogeneic transplantation: we need the proof in the pudding. Chimerism. 2013 Jul-Sep; 4(3):109-10. PMID: 23511912.
      Citations: 1     Fields:    Translation:Humans
    70. Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, Wickrema A, van Besien K. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9. PMID: 23088744.
      Citations: 8     Fields:    Translation:HumansCells
    71. Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):831-7. PMID: 23454184.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    72. van Besien K, Shore T, Cushing M. Peripheral-blood versus bone marrow stem cells. N Engl J Med. 2013 01 17; 368(3):287-8. PMID: 23323912.
      Citations: 2     Fields:    Translation:Humans
    73. Artz AS, van Besien K. Pre-transplant serum ferritin is prognostic but is it useful? Leuk Lymphoma. 2013 Jun; 54(6):1133-4. PMID: 23216268.
      Citations:    Fields:    Translation:Humans
    74. van Besien K. Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology Am Soc Hematol Educ Program. 2013; 2013:56-62. PMID: 24319163.
      Citations: 18     Fields:    Translation:Humans
    75. Churpek JE, Nickels E, Marquez R, Rojek K, Liu B, Lorenz R, Lepore J, Madzo J, Wickrema A, Artz AS, van Besien K, Godley LA. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012 Dec 20; 120(26):5247-9. PMID: 23258901.
      Citations: 6     Fields:    Translation:Humans
    76. Muffly LS, Boulukos M, Swanson K, Kocherginsky M, Cerro PD, Schroeder L, Pape L, Extermann M, Van Besien K, Artz AS. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant. 2013 Mar; 19(3):429-34. PMID: 23160006.
      Citations: 43     Fields:    Translation:Humans
    77. Geslain R, Uddin S, Liu H, Jiang H, van Besien K, Pan T, Wickrema A. Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. Cytokine. 2013 Jan; 61(1):329-35. PMID: 23148990.
      Citations: 7     Fields:    Translation:HumansCells
    78. Van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013 May; 19(5):682-91. PMID: 23142329.
      Citations: 13     Fields:    Translation:Humans
    79. van Besien K. cGVHD of skin: simple tools, great advances. Blood. 2012 Sep 27; 120(13):2537-8. PMID: 23019199.
      Citations:    Fields:    Translation:Humans
    80. Morawa E, Martin P, Gergis U, van Besien K, Shore T. Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. Leuk Lymphoma. 2013 Apr; 54(4):885-8. PMID: 22897727.
      Citations: 2     Fields:    Translation:Humans
    81. Dierickx D, van Besien K. Therapeutic drug monitoring: a way to improve long-term immunological balance? Leuk Lymphoma. 2013 Jan; 54(1):5-6. PMID: 22857003.
      Citations:    Fields:    Translation:HumansCells
    82. Villa CH, Shore T, Van Besien K, Cushing M. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1867-75. PMID: 22796644.
      Citations: 4     Fields:    Translation:Humans
    83. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81. PMID: 22571201.
      Citations: 339     Fields:    Translation:HumansCTClinical Trials
    84. Richa EM, Kunnavakkam R, Godley LA, Kline J, Odenike O, Larson RA, Nguyen V, Stock W, Wickrema A, Van Besien K, Artz AS. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15. PMID: 22548695.
      Citations: 3     Fields:    Translation:Humans
    85. Pai RK, van Besien K, Hart J, Artz AS, O'Donnell PH. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1552-7. PMID: 22280517.
      Citations: 8     Fields:    Translation:Humans
    86. Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50. PMID: 21913806.
      Citations: 5     Fields:    Translation:Humans
    87. Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PN. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1255-64. PMID: 22198543.
      Citations: 9     Fields:    Translation:Humans
    88. van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21. PMID: 22079470.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    89. van Besien K. Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr Opin Oncol. 2011 Nov; 23(6):681-91. PMID: 21946246.
      Citations: 7     Fields:    Translation:Humans
    90. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, Artz AS, van Besien K. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45. PMID: 21976674.
      Citations: 57     Fields:    Translation:HumansCellsCTClinical Trials
    91. Jain N, van Besien K. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am. 2011 Oct; 25(5):1025-48, vi. PMID: 22054733.
      Citations: 5     Fields:    Translation:Humans
    92. Rezania K, Soliven B, Baron J, Lin H, Penumalli V, van Besien K. Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012 Mar; 53(3):371-80. PMID: 21864038.
      Citations: 6     Fields:    Translation:Humans
    93. van Besien K, Schouten V, Parsad S, Smith S, Odenike O, Artz AS. Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. Leuk Lymphoma. 2012 Jan; 53(1):158-9. PMID: 21749304.
      Citations: 4     Fields:    Translation:Humans
    94. van Besien K. Stem cell transplantation for indolent lymphoma: a reappraisal. Blood Rev. 2011 Sep; 25(5):223-8. PMID: 21641099.
      Citations: 1     Fields:    Translation:Humans
    95. Ramsdale E, Van Besien K. Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions. Leuk Lymphoma. 2011 Aug; 52(8):1415-7. PMID: 21599586.
      Citations:    Fields:    Translation:Humans
    96. Poiré X, van Besien K. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opin Biol Ther. 2011 Aug; 11(8):1099-111. PMID: 21702703.
      Citations: 8     Fields:    Translation:Humans
    97. Greinix HT, van Besien K, Elmaagacli AH, Hillen U, Grigg A, Knobler R, Parenti D, Reddy V, Theunissen K, Michallet M, Flowers ME. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1775-82. PMID: 21621629.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    98. van Besien K. Cord blood transplant: the glass is half full--can we do better? Leuk Lymphoma. 2011 Apr; 52(4):554-5. PMID: 21438826.
      Citations: 2     Fields:    Translation:Humans
    99. Ramsdale E, van Besien K, Smith SM. Personalized treatment of lymphoma: promise and reality. Semin Oncol. 2011 Apr; 38(2):225-35. PMID: 21421112.
      Citations: 3     Fields:    Translation:Humans
    100. van Besien K, Kenkre V, Artz AS. T-cell-depleted reduced-intensity conditioning transplantation for lymphoma: do donor lymphocyte infusions really matter? J Clin Oncol. 2011 Mar 20; 29(9):e243; author reply e244. PMID: 21343548.
      Citations:    Fields:    Translation:HumansCells
    101. Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter DL, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giralt S. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54. PMID: 21224011.
      Citations: 18     Fields:    Translation:Humans
    102. Kenkre VP, Horowitz S, Artz AS, Liao C, Cohen KS, Godley LA, Kline JP, Smith SM, Stock W, van Besien K. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22. PMID: 21142785.
      Citations: 8     Fields:    Translation:Humans
    103. O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9. PMID: 20919852.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    104. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6. PMID: 20837940.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    105. Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503. PMID: 20699125.
      Citations: 47     Fields:    Translation:Humans
    106. Poiré X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50. PMID: 20496994.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    107. Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers ME, Gupta V, Hsu JW, Jagasia M, Kitko CL, Maziarz RT, Rowley SD, Shaughnessy PJ, van Besien K, Weisdorf D, Lee SJ. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Jan; 17(1):124-32. PMID: 20601033.
      Citations: 18     Fields:    Translation:Humans
    108. Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006. PMID: 20536346.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    109. Godley LA, van Besien K. The next frontier for stem cell transplantation: finding a donor for all. JAMA. 2010 Apr 14; 303(14):1421-2. PMID: 20388899.
      Citations: 3     Fields:    Translation:Humans
    110. Dew A, van Besien K. Stem-cell transplantation for sickle cell disease. N Engl J Med. 2010 Mar 11; 362(10):955; author reply 956. PMID: 20220194.
      Citations:    Fields:    Translation:Humans
    111. Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu R, Giralt S. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):563-4. PMID: 20202482.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    112. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010 Feb 20; 28(6):1038-46. PMID: 20085936.
      Citations: 72     Fields:    Translation:Humans
    113. van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, Odenike T, Rich E, Stock W, Wickrema A, Artz AS. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17. PMID: 19821799.
      Citations: 22     Fields:    Translation:Humans
    114. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1455-64. PMID: 19822306.
      Citations: 20     Fields:    Translation:Humans
    115. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010 Jan; 16(1):35-45. PMID: 20053330.
      Citations: 26     Fields:    Translation:Humans
    116. Richa E, Papari M, Allen J, Martinez G, Wickrema A, Anastasi J, Van Besien K, Artz A. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1394-9. PMID: 19822298.
      Citations: 12     Fields:    Translation:Humans
    117. Sharma M, Moore J, Nguyen V, Van Besien K. Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. Am J Hematol. 2009 Sep; 84(9):614-6. PMID: 19676117.
      Citations: 4     Fields:    Translation:Humans
    118. Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A, Van Besien K, Dipersio J. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma. 2009 Sep; 50(9):1412-21. PMID: 19603345.
      Citations: 13     Fields:    Translation:Humans
    119. Loberiza FR, Lee SJ, Freytes CO, Giralt SA, Van Besien K, Kurian S, del Cerro P, Toro JJ, Williams LA, Ketelsen SW, Navarro WH, Rizzo JD. Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Aug; 15(8):903-9. PMID: 19589479.
      Citations: 3     Fields:    Translation:Humans
    120. O'Donnell PH, Swanson K, Josephson MA, Artz AS, Parsad SD, Ramaprasad C, Pursell K, Rich E, Stock W, van Besien K. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1. PMID: 19660716.
      Citations: 26     Fields:    Translation:HumansCells
    121. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):610-7. PMID: 19361753.
      Citations: 25     Fields:    Translation:Humans
    122. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):554-63. PMID: 19361747.
      Citations: 16     Fields:    Translation:Humans
    123. Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 May 21; 113(21):5074-82. PMID: 19270260.
      Citations: 48     Fields:    Translation:Humans
    124. Poiré X, van Besien K. Autologous transplant for primary mediastinal B-cell lymphoma. Expert Rev Hematol. 2009 Feb; 2(1):31-6. PMID: 21082992.
      Citations: 1     Fields:    
    125. Foss F, van Besien K. Reduced-intensity and nonmyeloablative conditioning regimens. Cancer Treat Res. 2009; 144:209-32. PMID: 19779868.
      Citations:    Fields:    Translation:HumansCells
    126. Poiré X, Artz A, Larson RA, Kline J, Odenike O, Rich E, Godley L, Stock W, van Besien K. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91. PMID: 19142796.
      Citations: 6     Fields:    Translation:Humans
    127. van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program. 2009; 610-8. PMID: 20008246.
      Citations: 5     Fields:    Translation:Humans
    128. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009 Jan; 15(1):109-17. PMID: 19135949.
      Citations: 33     Fields:    Translation:Humans
    129. Lazarus HM, Carreras J, Boudreau C, Loberiza FR, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings P, Serna DS, Horowitz MM, Rizzo JD. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008 Dec; 14(12):1323-33. PMID: 19041053.
      Citations: 8     Fields:    Translation:Humans
    130. Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, Rich ES, Stock W, Ulaszek J, Larson RA, van Besien K. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16. PMID: 18940674.
      Citations: 32     Fields:    Translation:Humans
    131. Calderwood MS, Mauer A, Tolentino J, Flores E, van Besien K, Pursell K, Weber SG. Epidemiology of vancomycin-resistant enterococci among patients on an adult stem cell transplant unit: observations from an active surveillance program. Infect Control Hosp Epidemiol. 2008 Nov; 29(11):1019-25. PMID: 18823273.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    132. van Besien K, Hari P. Nonmyeloablative conditioning for relapsed follicular lymphoma. Blood. 2008 Sep 15; 112(6):2585-6; author reply 2586-7. PMID: 18779408.
      Citations: 1     Fields:    Translation:Humans
    133. Nguyen V, van Besien K. Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft versus leukemia effects? Leuk Lymphoma. 2008 Sep; 49(9):1651-2. PMID: 18798096.
      Citations:    Fields:    Translation:Humans
    134. Dew A, Collins D, Artz A, Rich E, Stock W, Swanson K, van Besien K. Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. Biol Blood Marrow Transplant. 2008 Aug; 14(8):938-41. PMID: 18640578.
      Citations: 23     Fields:    Translation:Humans
    135. Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008 Aug; 14(8):904-12. PMID: 18640574.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    136. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008 Oct 01; 112(7):2667-74. PMID: 18621929.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    137. Rosenbaum C, Peace D, Rich E, Van Besien K. Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease. Biol Blood Marrow Transplant. 2008 Jun; 14(6):719-23. PMID: 18489998.
      Citations: 9     Fields:    Translation:Humans
    138. Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7. PMID: 18297531.
      Citations: 2     Fields:    Translation:Humans
    139. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008 Feb; 14(2):236-45. PMID: 18215784.
      Citations: 50     Fields:    Translation:Humans
    140. Kang JA, Zhou Y, Weis TL, Liu H, Ulaszek J, Satgurunathan N, Zhou L, van Besien K, Crispino J, Verma A, Low PS, Wickrema A. Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts. J Biol Chem. 2008 Mar 14; 283(11):6997-7006. PMID: 18174176.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    141. van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma. 2008; 49 Suppl 1:52-8. PMID: 18821433.
      Citations: 11     Fields:    Translation:Humans
    142. Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L, Odenike O, Pursell KJ, Larson RA, Stock W, van Besien K. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805. PMID: 17786717.
      Citations: 4     Fields:    Translation:Humans
    143. Gordon MK, Kraus M, van Besien K. Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors. Leuk Lymphoma. 2007 Apr; 48(4):816-8. PMID: 17454644.
      Citations: 2     Fields:    Translation:HumansCells
    144. Samara MA, Brennan JM, Van Besien K, Larson RA. Cardiac tamponade in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2007 Apr; 48(4):829-32. PMID: 17454648.
      Citations: 1     Fields:    Translation:Humans
    145. van Besien K, Schouten H. Follicular lymphoma: a historical overview. Leuk Lymphoma. 2007 Feb; 48(2):232-43. PMID: 17325883.
      Citations: 2     Fields:    Translation:Humans
    146. Margolin KA, van Besien K, Peace DJ. An introduction to foundation and industry-sponsored research: practical and ethical considerations. Hematology Am Soc Hematol Educ Program. 2007; 498-503. PMID: 18024671.
      Citations: 1     Fields:    
    147. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64. PMID: 16920562.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    148. van Besien K. Toxicity of high dose BCNU: how much is too much? Leuk Lymphoma. 2006 Aug; 47(8):1447-8. PMID: 16966249.
      Citations:    Fields:    Translation:Humans
    149. van Besien K. Standardizing chronic graft-versus-host disease. Future Oncol. 2006 Aug; 2(4):459-62. PMID: 16922612.
      Citations: 1     Fields:    Translation:Humans
    150. Danaher EH, Ferrans C, Verlen E, Ravandi F, van Besien K, Gelms J, Dieterle N. Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant. Oncol Nurs Forum. 2006 May 03; 33(3):614-24. PMID: 16676017.
      Citations: 34     Fields:    Translation:Humans
    151. Villano JL, Collins CA, Manasanch EE, Ramaprasad C, van Besien K. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol. 2006 May; 7(5):436-8. PMID: 16648049.
      Citations: 18     Fields:    Translation:Humans
    152. Navarro WH, Loberiza FR, Bajorunaite R, van Besien K, Vose JM, Lazarus HM, Rizzo JD. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):541-51. PMID: 16635789.
      Citations: 27     Fields:    Translation:Humans
    153. Van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev. 2006 Sep; 20(5):235-44. PMID: 16513231.
      Citations: 6     Fields:    Translation:Humans
    154. Artz AS, Kocherginsky M, Van Besien K. Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. Br J Haematol. 2006 Mar; 132(6):747-54. PMID: 16487176.
      Citations: 2     Fields:    Translation:Humans
    155. Schwake CJ, Eapen M, Lee SJ, Freytes CO, Giralt SA, Navarro WH, Rizzo JD, van Besien K, Loberiza FR. Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities. Biol Blood Marrow Transplant. 2005 Dec; 11(12):988-98. PMID: 16338621.
      Citations: 7     Fields:    Translation:Humans
    156. van Besien K, Deeg HJ. Hematopoietic stem cell transplantation for myelofibrosis. Semin Oncol. 2005 Aug; 32(4):414-21. PMID: 16202687.
      Citations: 2     Fields:    Translation:Humans
    157. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38. PMID: 16009946.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    158. van Besien K, Smith S, Lazarus HM. Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant. Curr Treat Options Oncol. 2005 Jul; 6(4):279-87. PMID: 15967081.
      Citations:    Fields:    Translation:Humans
    159. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005 Feb 15; 65(4):1570-6. PMID: 15735047.
      Citations: 41     Fields:    Translation:HumansCells
    160. Scarpace SL, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A, van Besien K, McCarthy PL. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma. 2005 Feb; 46(2):239-42. PMID: 15621807.
      Citations: 14     Fields:    Translation:Humans
    161. Van Besien K. Autologous and allogeneic stem cell transplantation in follicular lymphoma. Transfus Apher Sci. 2005 Feb; 32(1):45-53. PMID: 15737873.
      Citations: 1     Fields:    Translation:Humans
    162. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, van Besien K. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004 Dec 01; 104(12):3797-803. PMID: 15280203.
      Citations: 26     Fields:    Translation:Humans
    163. Van Besien K, Smith S, Anastasi J, Larson R, Thirman M, Odenike T, Stock W. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004 Jun 01; 103(11):4373-4. PMID: 15155474.
      Citations: 2     Fields:    Translation:HumansCells
    164. Van Besien K, Mehra R, Wadehra N, Stock W, Khouri I, Giralt S, Devine S, Wickrema A, Peace D, Sosman J, Gajewski J, Champlin R. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2004 Jun; 10(6):386-94. PMID: 15148492.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    165. Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology Am Soc Hematol Educ Program. 2004; 203-20. PMID: 15561684.
      Citations: 3     Fields:    Translation:Humans
    166. Bierman PJ, Sweetenham JW, Loberiza FR, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003 Oct 15; 21(20):3744-53. PMID: 12963703.
      Citations: 34     Fields:    Translation:Humans
    167. Baron BW, van Besien K, Hoffman PC, Kohn OF, Rossof AH, Baron JM. Thrombotic thrombocytopenic purpura after cephalosporin administration: a possible relationship. Transfusion. 2003 Sep; 43(9):1317-21. PMID: 12919436.
      Citations: 2     Fields:    Translation:Humans
    168. van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, Freytes CO, Gibson J, Horowitz MM, Inwards DJ, Marks DI, Martino R, Maziarz RT, Molina A, Pavlovsky S, Pecora AL, Schouten HC, Shea TC, Lazarus HM, Rizzo JD, Vose JM. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003 Nov 15; 102(10):3521-9. PMID: 12893748.
      Citations: 73     Fields:    Translation:Humans
    169. de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7. PMID: 12599231.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    170. Levine JE, Harris RE, Loberiza FR, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003 Apr 01; 101(7):2476-82. PMID: 12456505.
      Citations: 24     Fields:    Translation:Humans
    171. G-Amlak M, Uddin S, Mahmud D, Damacela I, Lavelle D, Ahmed M, van Besien K, Wickrema A. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun. 2002 Oct 04; 297(4):760-4. PMID: 12359217.
      Citations: 12     Fields:    Translation:HumansCells
    172. Verma A, Deb DK, Sassano A, Kambhampati S, Wickrema A, Uddin S, Mohindru M, Van Besien K, Platanias LC. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol. 2002 Jun 15; 168(12):5984-8. PMID: 12055203.
      Citations: 36     Fields:    Translation:HumansCells
    173. Devine SM, Jahagirdar B, van Besien K. Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma. Blood. 2002 Jun 01; 99(11):4251-2; author reply 4252. PMID: 12043699.
      Citations:    Fields:    Translation:Humans
    174. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W, Maynard V, Jessop E, Peace D, Huml M, Thomason D, Chen YH, van Besien K. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002 Mar 15; 99(6):2255-8. PMID: 11877308.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials